{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:02:34Z","timestamp":1790798554698,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The present study evaluated the effect of different configuration setups of the Flow-Through Cell (USP IV) dissolution tester in developing <jats:italic>in vitro\u2013in vivo<\/jats:italic> correlation (IVIVC). A Biopharmaceutics Classification System (BCS) Class I Diltiazem (DTZ), formulated in extended-release (ER) gel-matrix system, was employed for this purpose. The study also assessed the validity and predictability of IVIVC employing both deconvolution- and convolution-based approaches. <jats:italic>In vitro<\/jats:italic> release was conducted in USP IV as open- or closed-loop setups, while the pharmacokinetic (PK) data were obtained from a previous fasted-state cross-over study conducted on 8 healthy male volunteers, after oral administration of ER matrix tablets against market product (Tildiem Retard\u00ae 90\u00a0mg). PK parameters (C<jats:sub>max<\/jats:sub>, AUC<jats:sub>0-t<\/jats:sub> and AUC<jats:sub>0-\u221e<\/jats:sub>) were predicted, and compared with actual data to establish the strength of correlation models. Results showed that DTZ release from ER products was influenced by operating the FTC in different configuration-setups, where\u2009\u2265\u200975% of labeled DTZ was released after 6\u00a0h and 12\u00a0h using the open- and closed-loop settings, respectively. Correlation between fraction-dissolved versus fraction-absorbed for both ER products displayed linear relation upon employing FTC open-loop setup. Convolution-based approach was more discriminative in predicting DTZ <jats:italic>in vivo<\/jats:italic> PK parameters with a minimal prediction error, compared to deconvolution-based approach. A successful trial to predict DTZ PKs from individual <jats:italic>in vitro<\/jats:italic> data performed in USP IV dissolution model was established, employing convolution technique. Basic principle of the convolution approach provides a simple and practical method for developing IVIVC, hence could be utilized for other BCS Class I extended-release drug products.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1208\/s12249-022-02361-2","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T06:37:38Z","timestamp":1658990258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Convolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester"],"prefix":"10.1208","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2021-6338","authenticated-orcid":false,"given":"Nesrin F.","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila H.","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"2361_CR1","doi-asserted-by":"publisher","unstructured":"Gomeni R, Bressolle-Gomeni F. Deconvolution analysis by non-linear regression using a convolution-based model: comparison of nonparametric and parametric approaches. AAPS J. 2019; Dec 9;22(1):9. https:\/\/doi.org\/10.1208\/s12248-019-0389-8","DOI":"10.1208\/s12248-019-0389-8"},{"issue":"1","key":"2361_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bdd.270","volume":"23","author":"N Sirisuth","year":"2002","unstructured":"Sirisuth N, Augsburger LL, Eddington ND. Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation. Biopharm Drug Dispos. 2002 Jan;23(1):1\u20138. https:\/\/doi.org\/10.1002\/bdd.270 (PMID: 11891668).","journal-title":"Biopharm Drug Dispos"},{"key":"2361_CR3","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: extended release oral dosage forms: development, evaluation, and application of invitro\/ in-vivo correlations. 1997. http:\/\/www.fda.gov\/downloads\/drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070239.pdf."},{"issue":"6","key":"2361_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/jps.2600520629","volume":"52","author":"JG Wagner","year":"1963","unstructured":"Wagner JG, Nelson E. Percent absorbed time plots derived from blood level and\/or urinary excretion data. J Pharm Sci. 1963;52(6):610\u20131. https:\/\/doi.org\/10.1002\/jps.2600520629.","journal-title":"J Pharm Sci"},{"issue":"6","key":"2361_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/jps.2600570602","volume":"57","author":"JCK Loo","year":"1968","unstructured":"Loo JCK, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci. 1968;57(6):918\u201328. https:\/\/doi.org\/10.1002\/jps.2600570602.","journal-title":"J Pharm Sci"},{"issue":"3","key":"2361_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF01312264","volume":"6","author":"DJ Cutler","year":"1978","unstructured":"Cutler DJ. Numerical deconvolution by least squares: use of prescribed input functions. J Pharmacokinet Biopharm. 1978;6(3):227\u201341. https:\/\/doi.org\/10.1007\/BF01312264.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"2361_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/BF01062554","volume":"16","author":"P Veng-Pedersen","year":"1988","unstructured":"Veng-Pedersen P. Linear and Nonlinear system approaches in pharmacokinetics: how much do they have to offer? I General considerations J Pharmacokinet Biopharm. 1988;16(5):413\u201332. https:\/\/doi.org\/10.1007\/BF01062554.","journal-title":"I General considerations J Pharmacokinet Biopharm"},{"issue":"3","key":"2361_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/BF02353672","volume":"24","author":"FN Madden","year":"1996","unstructured":"Madden FN, Godfrey KR, Chappell MJ, Hovorka R, Bates RA. A comparison of six deconvolution techniques. J Pharmacokinet Biopharm. 1996;24(3):283\u201399. https:\/\/doi.org\/10.1007\/BF02353672.","journal-title":"J Pharmacokinet Biopharm"},{"key":"2361_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1874126601004020038","volume":"4","author":"SA Qureshi","year":"2010","unstructured":"Qureshi SA. In vitro-in vivo correlation (IVIVC) and determining drug concentrations in blood from dissolution testing \u2013 a simple and practical approach. The Open Drug Deliv J. 2010;4:38\u201347.","journal-title":"The Open Drug Deliv J"},{"key":"2361_CR10","doi-asserted-by":"crossref","unstructured":"Emara LH, Taha NF, Mursi NM. Investigation of the effect of different flow through cell designs on the release of diclofenac sodium SR tablets. Dissolution Technol. 2009; May:23\u201331.","DOI":"10.14227\/DT160209P23"},{"issue":"1\u20132","key":"2361_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijpharm.2009.04.012","volume":"376","author":"M Kakhi","year":"2009","unstructured":"Kakhi M. Mathematical modeling of the fluid dynamics in the flow-through cell. Int J Pharm. 2009 Jul 6;376(1\u20132):22\u201340. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.04.012.","journal-title":"Int J Pharm"},{"issue":"9","key":"2361_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/jps.2600600902","volume":"60","author":"WL Chiou","year":"1971","unstructured":"Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971 Sep;60(9):1281\u2013302. https:\/\/doi.org\/10.1002\/jps.2600600902.","journal-title":"J Pharm Sci"},{"issue":"5","key":"2361_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1517\/14656566.6.5.765","volume":"6","author":"SA Claas","year":"2005","unstructured":"Claas SA, Glasser SP. Long-acting diltiazem HCl for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris. Expert Opin Pharmacother. 2005 May;6(5):765\u201376. https:\/\/doi.org\/10.1517\/14656566.6.5.765 (PMID: 15934903).","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2361_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/10717544.2016.1259371","volume":"24","author":"HO Ammar","year":"2017","unstructured":"Ammar HO, Haider M, Ibrahim M, El Hoffy NM. In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration. Drug Deliv. 2017 Nov;24(1):414\u201321. https:\/\/doi.org\/10.1080\/10717544.2016.1259371.","journal-title":"Drug Deliv"},{"key":"2361_CR15","doi-asserted-by":"publisher","unstructured":"Becker D, Zhang J, Heimbach T, Penland RC, Wanke C, Shimizu J, Kulmatycki K. Novel orally swallowable IntelliCap(\u00ae) device to quantify regional drug absorption in human GI tract using diltiazem as model drug. AAPS PharmSciTech. 2014 Dec;15(6):1490\u20137. doi: https:\/\/doi.org\/10.1208\/s12249-014-0172-1. Epub 2014 Jul 15.","DOI":"10.1208\/s12249-014-0172-1"},{"key":"2361_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"G Amidon","year":"1995","unstructured":"Amidon G, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320.","journal-title":"Pharm Res"},{"issue":"4","key":"2361_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ajps.2013.09.007","volume":"8","author":"X Han","year":"2013","unstructured":"Han X, Wang L, Sun Y, Liu X, Liu W, Du Y, Li L, Sun J. Preparation and evaluation of sustained-release diltiazem hydrochloride pellets. Asian J Pharm Sci. 2013;8(4):244\u201351. https:\/\/doi.org\/10.1016\/j.ajps.2013.09.007.","journal-title":"Asian J Pharm Sci"},{"key":"2361_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0168-3659(95)00041-6","volume":"36","author":"N Follonier","year":"1995","unstructured":"Follonier N, Doelker E, Cole ET. Various ways of modulating the release of diltiazem hydrochloride from hot-melt extruded sustained release pellets prepared using polymeric materials. J Control Release. 1995;36:243\u201350. https:\/\/doi.org\/10.1016\/0168-3659(95)00041-6.","journal-title":"J Control Release"},{"issue":"1","key":"2361_CR19","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.1208\/pt060105","volume":"6","author":"SM Al-Saidan","year":"2005","unstructured":"Al-Saidan SM, Krishnaiah YS, Patro SS, Satyanaryana V. In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride. AAPS Pharm Sci Tech. 2005;6(1):E14\u201321. https:\/\/doi.org\/10.1208\/pt060105.","journal-title":"AAPS Pharm Sci Tech"},{"key":"2361_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF00610053","volume":"24","author":"P Hermann","year":"1983","unstructured":"Hermann P, Rodger SD, Remones G, Thenot JP, London DR, Morselli PL. Pharmacokinetic of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol. 1983;24:349\u201352. https:\/\/doi.org\/10.1007\/BF00610053.","journal-title":"Eur J Clin Pharmacol"},{"key":"2361_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jps.2600760205","volume":"76","author":"K Murata","year":"1987","unstructured":"Murata K, Noda K, Kohno K, Samejima M. Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models. J Pharm Sci. 1987;76:109\u201313. https:\/\/doi.org\/10.1002\/jps.2600760205.","journal-title":"J Pharm Sci"},{"key":"2361_CR22","doi-asserted-by":"publisher","unstructured":"Caramella C, Ferrari F, Bonferoni MC, Sangalli ME, De Bernardi di Valserra M, Feletti F, Galmozzi MR. In vitro\/in vivo correlation of prolonged release dosage forms containing diltiazem HCI. Biopharm Drug Dispos 1993; 14: 143\u2013160. https:\/\/doi.org\/10.1002\/bdd.2510140206.","DOI":"10.1002\/bdd.2510140206"},{"issue":"8","key":"2361_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.2042-7158.1998.tb03998.x","volume":"50","author":"K Yu","year":"1998","unstructured":"Yu K, Gebert M, Altaf SA, Wong D, Friend DR. Optimization of sustained-release diltiazem formulations in man by use of an in-vitro\/in-vivo correlation. J Pharm Pharmacol. 1998 Aug;50(8):845\u201350. https:\/\/doi.org\/10.1111\/j.2042-7158.1998.tb03998.x.","journal-title":"J Pharm Pharmacol"},{"key":"2361_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jconrel.2003.12.026","volume":"95","author":"O Korhonen","year":"2004","unstructured":"Korhonen O, Kanerva H, Vidgren M, Urtti A, Ketolainen J. Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. J Control Release. 2004;95:515\u201320. https:\/\/doi.org\/10.1016\/j.jconrel.2003.12.026.","journal-title":"J Control Release"},{"key":"2361_CR25","doi-asserted-by":"publisher","unstructured":"Rafiq M, Wahab A,Rehman N-Ur, Hussain A, Muhammad S. In vitro and in vivo evaluation of two sustained release formulations of diltiazem HCl. AJPP. 2010; Sep 4(9):678\u2013694. https:\/\/doi.org\/10.5897\/AJPP.9000178.","DOI":"10.5897\/AJPP.9000178"},{"key":"2361_CR26","doi-asserted-by":"publisher","unstructured":"Mircioiu C, Anuta V, Mircioiu I, Nicolescu A, Fotaki N. In vitro-in vivo correlations based on in vitro dissolution of parent drug diltiazem and pharmacokinetics of its metabolite. Pharmaceutics. 2019; Jul16;11(7):344. https:\/\/doi.org\/10.3390\/pharmaceutics11070344.","DOI":"10.3390\/pharmaceutics11070344"},{"key":"2361_CR27","unstructured":"USP. Diltiazem Tablets and Extended-Release Capsules monogrphs. USP 28 - The United States Pharmacopeial Convention, Inc. Rockville, MD. 2005:655\u2013658."},{"issue":"10","key":"2361_CR28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/10837450.2017.1341523","volume":"23","author":"LH Emara","year":"2018","unstructured":"Emara LH, El-Ashmawy AA, Taha NF. Stability and bioavailability of diltiazem\/polyethylene oxide matrix tablets. Pharm Dev Technol. 2018 Dec;23(10):1057\u201366. https:\/\/doi.org\/10.1080\/10837450.2017.1341523.","journal-title":"Pharm Dev Technol"},{"key":"2361_CR29","doi-asserted-by":"publisher","first-page":"012","DOI":"10.7324\/JAPS.2015.50703","volume":"5","author":"LH Emara","year":"2015","unstructured":"Emara LH, El-Ashmawy AA, Taha NF. A five-year stability study of controlled-release diltiazem hydrochloride tablets based on polyethylene oxide. J App Pharm Sci. 2015;5:012\u201322. https:\/\/doi.org\/10.7324\/JAPS.2015.50703.","journal-title":"J App Pharm Sci"},{"key":"2361_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/s0731-7085(98)00011-9","volume":"17","author":"N Anderson","year":"1998","unstructured":"Anderson N, Bauer M, Boussac N, Malek RK, Munden P, Sardaro M. An evaluation of fit factors and dissolution efficiency for the comparison of in-vitro dissolution profiles. J Pharm Biomed Anal. 1998;17:811\u201322. https:\/\/doi.org\/10.1016\/s0731-7085(98)00011-9.","journal-title":"J Pharm Biomed Anal"},{"issue":"10","key":"2361_CR31","first-page":"594","volume":"47","author":"K Khan","year":"1972","unstructured":"Khan K, Rhodes CT. Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv. 1972;47(10):594\u2013607.","journal-title":"Pharm Acta Helv"},{"issue":"2","key":"2361_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123\u201333. https:\/\/doi.org\/10.1016\/S0928-0987(01)00095-1.","journal-title":"Eur J Pharm Sci"},{"key":"2361_CR33","first-page":"64","volume":"20","author":"JW Moore","year":"1996","unstructured":"Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20:64\u201374.","journal-title":"Pharm Technol"},{"key":"2361_CR34","unstructured":"Wagner JG. Biopharmaceutics and relevant pharmacokinetics. Hamilton: Drug Intelligence; 1971."},{"key":"2361_CR35","doi-asserted-by":"publisher","unstructured":"Taha NF, Emam MF, Emara LH. A novel combination of Soluplus\u00ae\/Poloxamer for Meloxicam solid dispersions via hot melt extrusion for rapid onset of action. Part 2: comparative bioavailability and IVIVC, Drug Dev Ind Pharm. 2020;46:8, 1362\u20131372. https:\/\/doi.org\/10.1080\/03639045.2020.1791164.","DOI":"10.1080\/03639045.2020.1791164"},{"issue":"12","key":"2361_CR36","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1002\/jps.22209","volume":"99","author":"M Ostrowski","year":"2010","unstructured":"Ostrowski M, Wilkowska E, Baczek T. The influence of averaging procedure on the accuracy of IVIVC predictions: immediate release dosage form case study. J Pharm Sci. 2010;99(12):5040\u20135. https:\/\/doi.org\/10.1002\/jps.22209.","journal-title":"J Pharm Sci"},{"key":"2361_CR37","unstructured":"Gohel M, Delvadia RR, Parikh DC, Zinzuwadia MM, Soni CD, Sarvaiya KG, Mehta NR, Joshi BR, Dabhi AS. Simplified mathematical approach for back calculation in Wagner-Nelson method. Pharmaceutical reviews. 2005;3 (2)."},{"key":"2361_CR38","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/jps.2600531126","volume":"53","author":"JG Wagner","year":"1964","unstructured":"Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single dose of drugs. J Pharm Sci. 1964;53:1392\u2013403. https:\/\/doi.org\/10.1002\/jps.2600531126.","journal-title":"J Pharm Sci"},{"issue":"9","key":"2361_CR39","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s12272-009-1918-2","volume":"32","author":"ER Bendas","year":"2009","unstructured":"Bendas ER. Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride. Arch Pharm Res. 2009 Sep;32(9):1317\u201329. https:\/\/doi.org\/10.1007\/s12272-009-1918-2.","journal-title":"Arch Pharm Res"},{"key":"2361_CR40","unstructured":"CDER (Center for Drug Evaluation and Research), Guidance for Industrial Extended-Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro\/In Vivo Correlations, Food and Drug Administration, Rockville, MD (1997)."},{"key":"2361_CR41","doi-asserted-by":"crossref","unstructured":"Banaker UV (Ed.). Pharmaceutical dissolution testing, Marcel Dekker, New York, 1992:53\u2013107.","DOI":"10.1201\/b14198-4"},{"key":"2361_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/BF00613518","volume":"31","author":"A Gordin","year":"1986","unstructured":"Gordin A, Pohto P, Sundberg S, Nykanen S, Haataja H, Mannisto P. Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. Eur J Clin Pharmacol. 1986;31:423\u20136. https:\/\/doi.org\/10.1007\/BF00613518.","journal-title":"Eur J Clin Pharmacol"},{"key":"2361_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/BF00202171","volume":"48","author":"OE Della Paschoa","year":"1995","unstructured":"Della Paschoa OE, Luckow V, Trenk D, Jahnchen E, Santos SR. Prolongation of the PQ interval as a measure of therapeutic inequivalence between two formulations of diltiazem. Eur J Clin Pharmacol. 1995;48:45\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2361_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.fjps.2018.03.001","volume":"4","author":"V Rastogi","year":"2018","unstructured":"Rastogi V, Yadav P, Lal N, Rastogi P, Singh BK, Verma N, Verma A. Mathematical prediction of pharmacokinetic parameters-an in-vitro approach for investigating pharmaceutical products for IVIVC. Future J Pharm Sci. 2018;4(2):175\u201384. https:\/\/doi.org\/10.1016\/j.fjps.2018.03.001.","journal-title":"Future J Pharm Sci"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02361-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-022-02361-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02361-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T16:18:19Z","timestamp":1666109899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-022-02361-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1208\/s12249-022-02361-2","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"12 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"202"}}